5 chapters across the catalog
The World Health Organization reports that extreme drug-resistant tuberculosis has spread to 70 countries. The hosts critique the WHO's stance, which blames private doctors in India for improper prescribing habits, suggesting the organization is protecting the interests of specific pharmaceutical regimes.
Researchers have used artificial intelligence to identify a new antibiotic effective against the drug-resistant bacteria Acinetobacter baumannii. The hosts critique the media's personification of bacteria as "smart" and clarify that the process is actually high-speed machine learning rather than true intelligence. While successful in mice, the drug faces years of human clinical trials and the challenge of pharmaceutical profitability.
Antibiotic Production, Fermentation and Drug Resistance
The United States has largely ceased domestic production of antibiotics, outsourcing the process to China due to their expertise in fermentation. This economic shift has led to a reliance on imported antibiotic salts, which are then processed in India. Substandard generic doses are cited as a primary driver of global drug resistance, as patients receive ineffective levels of medication.
Antibiotic Resistance, Drug Company R&D Priorities
The CDC is warning of a highly resistant strain of E. coli found in a Pennsylvania woman. The discussion criticizes pharmaceutical companies like Pfizer for abandoning antibiotic research in favor of more profitable long-term treatments for chronic conditions.
Tuberculosis Pandemic, Global Vaccine Plan, and Man-Made Diseases
The hosts investigate a reported global plan by the World Health Organization to address a predicted tuberculosis pandemic. They highlight claims that drug-resistant TB is a "man-made" problem and discuss historical instances of vaccine contamination, such as the Lubeck accident and a more recent incident involving Baxter and bird flu.
